ArticleClinical, cosmetic and investigational dermatology2025
Dupilumab for Atopic Dermatitis with Twenty-Nail Dystrophy: A Case Report.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Efficacy of Dupilumab in Treating Trachyonychia and Other Nail Dystrophies: A Systematic Review of Case Reports.Cureus · 2026Review
- Dupilumab for Atopic Dermatitis-Associated Nail Dystrophy: A Case Report.International medical case reports journal · 2026Article
- Nail dystrophy successfully treated with dupilumab in pediatric atopic dermatitis: case series and literature review.Frontiers in immunology · 2026Review
- Different clinical phenotypes of nail abnormalities in patients with severe atopic dermatitis: a single-centre cross-sectional study.Postepy dermatologii i alergologii · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) typically presents with cutaneous symptoms, but nail changes, particularly twenty-nail dystrophy (TND), are often overlooked. We report a case of a 40-year-old woman with a 3-year history of eczematous erythema and pruritus around the nails, accompanied by nail deformities. She had elevated serum IgE levels (2250 IU/mL) and dermatoscopic findings of thickened yellowish nails with splinter hemorrhages. Diagnosed with AD and TND, she received dupilumab after failing conventional treatments. Within 2 weeks, she experienced significant itch relief, and by 5 months, nearly complete nail recovery was observed, with serum IgE levels decreasing to 823 IU/mL. This case highlights the importance of recognizing nail involvement in AD, suggesting that periungual eczema and TND may represent a distinct phenotype. Dupilumab shows promise as an effective treatment for this condition, warranting further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.